The Indian Beta Drugs signed a memorandum on setting up of a oncology drugs production joint venture in Uzbekistan with local partners, Gazeta.uz said.
The 72 million tablets and capsules per year capacity full cycle production unit is located in Bekabad, city of Tashkent province and is equipped in line with Good Manufacturing Practices (GMP).
The company plans to develop import-substituting antitumor drugs for the treatment of breast cancer, leukemia, colorectal cancer, stomach cancer, prostate and other cancers.
"We are expecting our prices to be competitive, approximately 20-25% cheaper than the foreign analogues. We are also planning to export products," said Rahul Batra, the commercial director at Beta Drugs.
"We have been closely following the trends in Uzbekistan’s pharmaceutical sector and very positively value your government's efforts aimed at providing the public with socially important quality and affordable medicines," said Vijay Batra, managing director at Beta Drugs."
Beta Drugs is a manufacturer of antitumor drugs with high added value. The company has four plants producing active substances, parenteral drugs, tablets, capsules and liquids.
